DR. REDDY'S LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,253 INR | +0.58% |
|
+5.23% | +7.85% |
| Sales 2024 * | 279B 3.34B | Sales 2025 * | 299B 3.58B | Capitalization | 1,041B 12.49B |
|---|---|---|---|---|---|
| Net income 2024 * | 54.64B 655M | Net income 2025 * | 56.74B 681M | EV / Sales 2024 * | 3.5 x |
| Net cash position 2024 * | 66.43B 797M | Net cash position 2025 * | 105B 1.26B | EV / Sales 2025 * | 3.13 x |
| P/E ratio 2024 * |
19
x | P/E ratio 2025 * |
18.3
x | Employees | 25,863 |
| Yield 2024 * |
0.65% | Yield 2025 * |
0.7% | Free-Float | 91.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on Dr. Reddy's Laboratories Limited
More recommendations
More press releases
More news
| 1 day | +0.58% | ||
| 1 week | +5.23% | ||
| Current month | +1.59% | ||
| 1 month | +3.40% | ||
| 3 months | +6.82% | ||
| 6 months | +16.11% | ||
| Current year | +7.85% |
1 week
5 923.00
6 310.00
1 month
5 881.156 310.00
Current year
5 523.456 505.50
1 year
4 383.406 505.50
3 years
3 655.006 505.50
5 years
2 352.006 505.50
10 years
1 888.006 505.50
| Managers | Title | Age | Since |
|---|---|---|---|
Erez Israeli
CEO | Chief Executive Officer | 57 | 02/18/02 |
Parag Agarwal
DFI | Director of Finance/CFO | - | 02/20/02 |
| Chairman | 56 | 18/93/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gunupati Prasad
CHM | Chairman | 63 | 08/86/08 |
| Chairman | 56 | 18/93/18 | |
Kalpana Morparia
BRD | Director/Board Member | 73 | 05/07/05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.02% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 6,253 | +0.58% | 8,637 |
| 25/24/25 | 6,217 | +4.47% | 27,972 |
| 24/24/24 | 5,951 | -0.05% | 6,843 |
| 23/24/23 | 5,954 | -1.01% | 2,144 |
| 22/24/22 | 6,015 | +1.22% | 7,436 |
Delayed Quote Bombay S.E., April 26, 2024 at 03:30 pm IST
More quotes
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows:
- sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines;
- sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services;
- other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc.
Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Sector
Pharmaceuticals
Calendar
07/05/2024
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
6,253
INR
Average target price
6,005
INR
Spread / Average Target
-3.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.85% | 12.49B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- DRREDDY Stock
